A high dose of Wegovy helped people lose 21% of their weight. It was just approved.
诺和诺德诺和诺德(US:NVO) MarketWatch·2026-03-20 02:42

诺和诺德与礼来在GLP-1药物领域的竞争 - 诺和诺德计划推出7.2毫克剂量的Wegovy，以增强其在GLP-1药物市场的竞争力 [1] - 该剂量的Wegovy将直接与礼来公司的GLP-1注射药物形成竞争关系 [1]